Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07388628Recruiting

ARTICE® Real Data Collection & Observational Trial, Phase 4 Study

Role: lead

NCT05442710Phase 2Recruiting

Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy

Role: lead

NCT06143137Recruiting

Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outcome Follow up

Role: lead

All 3 trials loaded